The mechanism of CTGO in treating eczema may be related to regulating related inflammatory factors, promoting the Th1 and Th2 immune balance, and affecting the TLR4/NF-κB signaling pathway. This evidence concerns the gene TLR4 and Eczematoid dermatitis.